Anzeige
Mehr »
Sonntag, 24.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14355 | ISIN: FI4000153309 | Ticker-Symbol: 4FR
Frankfurt
22.08.25 | 08:12
2,650 Euro
+3,92 % +0,100
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FARON PHARMACEUTICALS OY Chart 1 Jahr
5-Tage-Chart
FARON PHARMACEUTICALS OY 5-Tage-Chart
RealtimeGeldBriefZeit
2,6302,71023.08.

Aktuelle News zur FARON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiFaron Pharmaceuticals Ltd: Notice of Half-Year Financial Results 354Faron Pharmaceuticals will publish its half-year financial results for January-June 2025 on Wednesday 27 August 2025 TURKU, FI / ACCESS Newswire / August 19, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First...
► Artikel lesen
MoFaron secures FDA pathway for lead cancer therapy3
MoFaron Pharmaceuticals: Inside Information: Faron to Advance Bexmarilimab into a Registrational Phase 2/3 Study in Treatment-Naïve HR-MDS after Positive Meeting with the FDA338Inside Information: Accelerated approval pathway confirmed for frontline patients with CR + CReq, and Overall Survival as primary endpoints TURKU, FI / ACCESS Newswire / August 18, 2025 / Faron Pharmaceuticals...
► Artikel lesen
08.08.Faron Pharmaceuticals Ltd: Holding(s) in Company271TURKU, FI / ACCESS Newswire / August 8, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Faron Pharmaceuticals Ltd | Company announcement | August 08, 2025 at 17:00:00 EESTTR-1: Standard form for notification...
► Artikel lesen
08.08.Faron Pharmaceuticals: Faron Announces Extension to its Key Patent Family around Bexmarilimab and Targeting Clever-1 in Cancers with a New US Patent Granted278Faron has been granted a patent for treatment of Clever-1 positive cancers with bexmarilimab and related structures in the USA.This extends key patent rights around bexmarilimab from an initial 2037...
► Artikel lesen
07.08.Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds267TURKU, FI / ACCESS Newswire / August 7, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the...
► Artikel lesen
FARON PHARMACEUTICALS Aktie jetzt für 0€ handeln
06.08.AIM Market Roundup: Catenai, Europa Oil & Gas, Faron Pharma1
06.08.Faron Pharmaceuticals reports higher remission rates in cancer trial2
06.08.Faron Pharmaceuticals: Inside Information: Faron to Present Updated BEXMAB Data in Frontline HR-MDS to FDA; Complete Remission Rate Substantially Increased to 43%314Inside Information: Complete remission rate in frontline HR-MDS patients rose from 28% to 43% in latest data cut, confirming the deepening of responses over time. TURKU, FI / ACCESS Newswire / August...
► Artikel lesen
30.07.Faron Pharmaceuticals: Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at ESMO 2025317Presentation to include the first full pharmacokinetic and pharmacodynamic (PK/PD) data from the BEXMAB study; supports bexmarilimab's advancement into Phase III TURKU, FI / ACCESS Newswire / July 30...
► Artikel lesen
09.07.Faron Pharmaceuticals: Faron Announces Acceptance of Two Studies Involving Bexmarilimab, One of Them as an Oral Presentation, at the 19th International Congress of Immunology 2025327TURKU, FI / ACCESS Newswire / July 9, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - The oral presentation and poster showcase bexmarilimab's dual attack on cancer with new mechanistic data from...
► Artikel lesen
02.07.IN BRIEF: Faron Pharmaceuticals Chair Tuomo Patsi adds to shareholding-
02.07.Faron Pharmaceuticals Ltd: Director Dealing290TURKU, FINLAND / ACCESS Newswire / July 2, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces...
► Artikel lesen
30.06.Faron Pharmaceuticals Ltd: Director/PCA Dealing228TURKU, FINLAND / ACCESS Newswire / June 30, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces...
► Artikel lesen
30.06.Faron Pharmaceuticals: Faron-Supported Research in Theranostics Identifies Secreted Clever-1 as an Independent Driver of Immune Evasion in Cancer, Deepening the Understanding of Bexmarilimab's Mode of Action244Study details how bexmarilimab treatment reduces circulating sClever-1 in patients with cancer, a key factor in T-cell suppression and PD-1 therapy resistance TURKU, FINLAND / ACCESS Newswire / June...
► Artikel lesen
12.06.Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025260TURKU, FI / ACCESS Newswire / June 12, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancementMedian...
► Artikel lesen
05.06.Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation247TURKU, FI / ACCESS Newswire / June 5, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies...
► Artikel lesen
05.06.Faron Pharma founders donate shares, sell stake3
05.06.Gründer von Faron Pharma spenden Aktien und verkaufen Anteile4
03.06.Faron Pharmaceuticals erweitert Aktienanzahl durch neue Registrierung2
Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1